Genetix Biotherapeutics
Developing and commercializing curative gene therapies for rare diseases.
Company facts
- Founded
- 1992
- Employees
- 300
- Headquarters
- United States
- CEO
- David Meek
- Type
- Private
- Funding
- Private Equity · $50M · 2025
About
Genetix Biotherapeutics is a commercial-stage biotherapeutics company dedicated to transforming lives through curative gene therapies for patients with rare, genetic diseases. Formerly known as bluebird bio, the company has returned to its foundational roots while sharpening its focus on delivering life-changing genetic therapies to patients who need them most. The company has developed three FDA-approved genetic therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy (CALD). These first-in-class, one-time administered therapies treat the underlying cause of disease and are designed using the patient's own blood stem cells. After more than 30 years of research and clinical development, these therapies represent a new frontier in treating serious rare genetic conditions. On June 2nd, 2025, Genetix Biotherapeutics marked a pivotal moment by announcing a newly appointed leadership team and transitioning to a privately held company. This move has strengthened the organization both financially and operationally, positioning it to unlock the full potential of its transformative genetic therapies through improved commercial execution and expanded patient access.